ZA202002080B - Glp-2 analogs and peptibodies for administration before, during or after surgery - Google Patents

Glp-2 analogs and peptibodies for administration before, during or after surgery

Info

Publication number
ZA202002080B
ZA202002080B ZA2020/02080A ZA202002080A ZA202002080B ZA 202002080 B ZA202002080 B ZA 202002080B ZA 2020/02080 A ZA2020/02080 A ZA 2020/02080A ZA 202002080 A ZA202002080 A ZA 202002080A ZA 202002080 B ZA202002080 B ZA 202002080B
Authority
ZA
South Africa
Prior art keywords
glp
analogs
surgery
small intestine
during
Prior art date
Application number
ZA2020/02080A
Other languages
English (en)
Inventor
Clark Pan
Angela Norton
Bettina Strack-Logue
Clément Olivier
Original Assignee
Shire Nps Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Nps Pharmaceuticals Inc filed Critical Shire Nps Pharmaceuticals Inc
Publication of ZA202002080B publication Critical patent/ZA202002080B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2020/02080A 2017-11-06 2020-05-04 Glp-2 analogs and peptibodies for administration before, during or after surgery ZA202002080B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762582055P 2017-11-06 2017-11-06
PCT/US2018/059175 WO2019090209A1 (en) 2017-11-06 2018-11-05 Glp-2 analogs and peptibodies for administration before during, or after surgery

Publications (1)

Publication Number Publication Date
ZA202002080B true ZA202002080B (en) 2025-11-26

Family

ID=66332372

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/02080A ZA202002080B (en) 2017-11-06 2020-05-04 Glp-2 analogs and peptibodies for administration before, during or after surgery

Country Status (14)

Country Link
US (1) US11660328B2 (cg-RX-API-DMAC7.html)
EP (1) EP3706774A4 (cg-RX-API-DMAC7.html)
JP (2) JP7296958B2 (cg-RX-API-DMAC7.html)
KR (1) KR102825098B1 (cg-RX-API-DMAC7.html)
CN (1) CN111629745A (cg-RX-API-DMAC7.html)
AR (1) AR113835A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018360744A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020008936A2 (cg-RX-API-DMAC7.html)
CA (1) CA3079523A1 (cg-RX-API-DMAC7.html)
IL (1) IL274098B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004620A (cg-RX-API-DMAC7.html)
TW (1) TWI911137B (cg-RX-API-DMAC7.html)
WO (1) WO2019090209A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002080B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018321841A1 (en) * 2017-08-22 2020-02-20 Shire-Nps Pharmaceuticals, Inc. GLP-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
WO2020086741A1 (en) * 2018-10-24 2020-04-30 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
EP4126003A1 (en) * 2020-03-30 2023-02-08 Zealand Pharma A/S Glp-1/glp-2 dual agonists
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
WO2021263040A1 (en) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Stable peptibody formulations
CN115636876A (zh) * 2021-07-20 2023-01-24 重庆派金生物科技有限公司 胰高血糖素样肽-2突变体的定向化学偶联物及其应用
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025181330A1 (en) * 2024-02-29 2025-09-04 Vectivbio Ag Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1809318T3 (da) * 2004-11-01 2013-09-08 Nps Pharma Inc Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
JP2009510999A (ja) * 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
AU2006321743A1 (en) * 2005-10-24 2007-06-14 Centocor, Inc. GLP-2 mimetibodies, polypeptides, compositions, methods and uses
US7812121B2 (en) * 2006-08-31 2010-10-12 Baker Audrey E GLP-2 mimetibodies, polypeptides, compositions, methods and uses
JP2008247789A (ja) * 2007-03-30 2008-10-16 Kissei Pharmaceut Co Ltd クローン病に伴う腸管狭窄の進展抑制用医薬組成物
ES2687651T3 (es) * 2011-09-12 2018-10-26 Amunix Operating Inc. Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
US10137170B2 (en) * 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도

Also Published As

Publication number Publication date
IL274098B1 (en) 2024-08-01
US20210169986A1 (en) 2021-06-10
AR113835A1 (es) 2020-06-17
EP3706774A4 (en) 2021-09-08
TW201922279A (zh) 2019-06-16
KR20200085763A (ko) 2020-07-15
MX2020004620A (es) 2020-10-12
JP7296958B2 (ja) 2023-06-23
CA3079523A1 (en) 2019-05-09
TWI911137B (zh) 2026-01-11
RU2020118172A (ru) 2021-12-08
KR102825098B1 (ko) 2025-06-26
AU2018360744A1 (en) 2020-05-07
JP7752152B2 (ja) 2025-10-09
CN111629745A (zh) 2020-09-04
IL274098B2 (en) 2024-12-01
JP2023107883A (ja) 2023-08-03
US11660328B2 (en) 2023-05-30
JP2021502389A (ja) 2021-01-28
WO2019090209A1 (en) 2019-05-09
BR112020008936A2 (pt) 2020-10-20
IL274098A (en) 2020-06-30
EP3706774A1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
MX2020004620A (es) Analogos y pepticuerpos de peptido 2 similar a glucagon (glp-2) para administracion antes, durante o despues de cirugia.
MX2019012081A (es) Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso.
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
MX2022000310A (es) Inhibidores de proteina bcl-2.
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
EP3946085A4 (en) SURGICAL SYSTEM AND METHOD FOR STABILIZATION AND FIXATION OF FRACTURES, JOINTS AND RECONSTRUCTIONS
PH12015500683A1 (en) Formula fortifier
WO2015023553A3 (en) Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules
WO2020026212A3 (en) Methods of preparing personalized blood vessels
WO2019108592A3 (en) Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
EA201692106A1 (ru) Пищевые продукты, системы, способы и наборы для замены электролитов
MX2020011453A (es) Combinaciones para tratar el cancer.
MX2022009064A (es) Procedimiento para preparar una composicion de consome que puede ser bombeada.
EA201700032A1 (ru) Универсальный кардиоплегический раствор (варианты)
BR112018016180A2 (en) aseptic protein drink and preparation method
EA201270016A1 (ru) Галогенированные алифатические карбоновые кислоты, их олигомеры и/или полимеры и их применение для девитализации внешних и внутренних новообразований
MX2020002606A (es) Composiciones inyectables de acetato de medroxiprogesterona y metodos de uso.
BR112015025288A2 (pt) vacina de campylobacter
MX2020002730A (es) Metodos de preparacion de composiciones que contienen timoquinona.
MX2018001041A (es) Concentrado que contiene alprostadil.
MX367120B (es) Pinzas para reparación percutánea del tendón de aquiles por mínima invasión.
AU2014101423A4 (en) Abalone blood flavoured ethyl alcohol.
Pena Tranexamic acid